<DOC>
	<DOCNO>NCT00695110</DOCNO>
	<brief_summary>The purpose pharmacokinetic study determine whether oral testosterone ester formulation use effectively treat men low testosterone .</brief_summary>
	<brief_title>Pharmacokinetic Study Oral Testosterone ( T ) Ester Formulations Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male , age 1868 Serum total testosterone less equal 275 ng/dL Significant intercurrent disease type , particular , liver , kidney heart disease , uncontrolled diabetes mellitus psychiatric illness . Abnormal prostate digital rectal examination , elevate PSA , AUA symptom score &gt; 15 , and/or history prostate cancer . Hematocrit &lt; 35 &gt; 50 % BMI &gt; 36 Serum transaminase &gt; 2 time upper limit normal serum bilirubin &gt; 2.0 mg/dL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>testosterone</keyword>
	<keyword>male hypogonadism</keyword>
	<keyword>low testosterone</keyword>
</DOC>